Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short-Term Debt issuances (2020 - 2022)

Guided Therapeutics' Short-Term Debt issuances history spans 3 years, with the latest figure at -$90000.0 for Q1 2022.

  • For Q1 2022, Short-Term Debt issuances rose 83.84% year-over-year to -$90000.0; the TTM value through Mar 2022 reached -$842000.0, changed N/A, while the annual FY2021 figure was -$1.5 million, 33.33% down from the prior year.
  • Short-Term Debt issuances for Q1 2022 was -$90000.0 at Guided Therapeutics, down from -$53000.0 in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at -$53000.0 in Q4 2021 and bottomed at -$557000.0 in Q1 2021.
  • The 3-year median for Short-Term Debt issuances is -$116000.0 (2020), against an average of -$210500.0.
  • The largest annual shift saw Short-Term Debt issuances soared 62.68% in 2021 before it soared 83.84% in 2022.
  • A 3-year view of Short-Term Debt issuances shows it stood at -$142000.0 in 2020, then skyrocketed by 62.68% to -$53000.0 in 2021, then crashed by 69.81% to -$90000.0 in 2022.
  • Per Business Quant, the three most recent readings for GTHP's Short-Term Debt issuances are -$90000.0 (Q1 2022), -$53000.0 (Q4 2021), and -$557000.0 (Q1 2021).